Fri Sep 13 14:48:08 UTC 2024: ## Granules India Stock Plunges After USFDA Inspection Raises Concerns
**Hyderabad, India** – Granules India, a leading pharmaceutical company, has seen its stock price plummet in recent days following a US Food and Drug Administration (USFDA) inspection that revealed significant deficiencies at one of its facilities.
The inspection resulted in the issuance of a Form 483, outlining six observations concerning critical aspects of the company’s manufacturing processes. These observations include issues with improper cleaning of equipment, failure to review discrepancies in the manufacturing process, and a lack of documented quality control procedures.
These findings have raised concerns amongst investors, who fear potential regulatory actions and disruptions to production. The company’s stock has fallen 15% in the past five days, erasing much of its recent gains.
Despite these challenges, Granules India remains committed to its growth strategy, focusing on expanding its core business, particularly in the formulation development segment. The company is also making significant investments in oncology and CNS/ADHD product development, expecting to launch several new products in the coming years.
**Experts believe that the company’s long-term prospects remain positive, but the USFDA inspection has created short-term uncertainty.** Granules India will need to address the concerns raised by the USFDA to regain investor confidence and maintain its growth trajectory.
**This article is for informational purposes only and should not be considered as investment advice.**
First Piper 